[Neonatal hypoxia and hemocoagulative changes].
Coagulation abnormalities with and without haemorrhagic manifestations have been frequently reported in newborn-infants affected by hypoxia. Particularly in postmature-infants and in those ones with acute asphyxia at birth, respiratory distress syndrome (RDS), intra-uterine growth retardation (IUGR) and cyanotic congenital heart disease (CCHD). A reduction of synthesis or a consumption of blood coagulation factors are the main causes of these abnormalities. The anomalies of platelet number and of their function, of haemostasis global tests, of coagulation factors and physiologic inhibitors levels, of fibrinogenesis and fibrinolysis are examined, including authors' studies and a review of literature too. The authors think platelet count, PT, PTT, fibrinogen, factor V and VIII, and PDF determinations are necessary laboratory investigations for newborn-infants with RDS or acute asphyxia for about the first week of life, because of the risk of consumption coagulopathy. In the other hypoxic newborns (IUGR, CCHD, postmature infants) platelets count, PT, PTT and serum PDF determinations could be enough in order to value any coagulation abnormalities presence.
Fichera
A
A
Istituto di Clinica Pediatrica II, Università di Catania, Italia.
Praticò
G
G
Sciacca
F
F
D001778:Blood Coagulation Disorders / Q000097:blood / Q000209:etiology*; D001792:Blood Platelets / Q000502:physiology*; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000209:etiology; D005337:Fibrin / Q000096:biosynthesis; D005342:Fibrinolysis; D006801:Humans; D000860:Hypoxia / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000097:blood / Q000209:etiology; D007235:Infant, Premature, Diseases / Q000097:blood / Q000209:etiology*; D012127:Respiratory Distress Syndrome, Newborn / Q000150:complications; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology*
D005337:Fibrin
Ipossia neonatale e modificazioni emocoagulative.